Day 1 Stream 1: Drug Discovery Innovation and Strategies, Enabling Technologies for Immuno-therapy, Autoimmune Diseases, Neuroscience & Oncology
- Innovative target discovery and discovery models in:
  - cancer immunotherapy
  - oncology
  - autoimmune diseases
- Target validation and lead optimisation novel strategies
- Toxicity studies in drug discovery
- Discovery of T-cell cancer immuno-therapy
- Emerging therapies for cancer
- Kinase inhibitors: applicability in cancer immunotherapy discovery, autoimmune and inflammatory diseases

Benefits to Attending
✓ Hear from and meet with the key innovators in drug discovery and medicinal chemistry. Attendees include Directors from Pfizer, Janssen, GlaxoSmithKline, Merck and AbbVie
✓ Discover collaborative solutions to target discovery and phenotypic and high content screening challenges. Our Congress brings together discovery experts to discuss new approaches to lead optimization, target validation and high content screening
✓ Discuss the latest innovations in computational chemistry and drug design. Our esteemed speakers will explore lead integration, targeted covalent inhibitors, DNA-encoded libraries and fragment and structure based design
✓ Unparalleled networking opportunities. This two-day congress offers dedicated networking breaks creating an interactive platform for scientific discussions and 1-2-1 meetings. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion
✓ A high-quality programme devised with the help of our esteemed advisory board. Presentations will cover areas including innovative discovery strategies in Cancer Immunotherapy, Autoimmune Diseases, Neuroscience & Oncology
✓ Co-located with our 2nd Annual Biomarkers USA Congress

FREE PRE-CONGRESS WEBINARS
Innovative Computational Approaches To Drug Discovery – Thursday 1st June, 4pm BST

Register here now>>

Day 1 Stream 2: Discovery Chemistry: Medicinal and Computational Chemistry
- Modern developments in medicinal chemistry
- Computational Chemical approaches to drug discovery
- Progressing from classical computational chemistry to data analysis and integration
- In-silico chemistry and molecular modelling for computer-aided drug design
- Designing informatics tools
- Structure-based drug design
- Fragment-based drug discovery
- Design and optimisation of inhibitors

Day 2 Stream 2: Discovery Chemistry: Medicinal Chemistry and Novel Approaches to Drug Design
- Protein kinases in immunology and oncology
- Inhibitor discovery strategies
- DNA-encoded libraries
- Targeted covalent inhibitors (TCIs)
- Novel approaches to drug design and development
- GPCR-targeted Drug Design
- Predictive assays

Meet Senior Decision Makers
Over 250 VPs, Directors & Global Heads from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

Drug Discovery
Assay Development
Target Identification
Phenotypic Screening

Medicinal Chemistry
Synthetic Chemistry
Computer aided drug design
Cheminformatics

Lead Generation
Candidate Analysis
Library Optimisation
Target Based Screening

Biologics Discovery
Data Analysis
Informatics
Compound Profiling

For booking details & registration fees please refer to the last page or visit:
www.discoveryusa-congress.com/marketing
2017 Confirmed and Reserved Speakers Include:

- Spiros Liras, Vice President, Medicinal Chemistry, Pfizer
- Michael Letavic, Scientific Director & Fellow, Janssen
- Mark Hurfe, Director, Computational Biology, GlaxoSmithKline
- Matthias Frech, Director, Molecular Interactions & Biophysics, Merck
- Anil Vasudevan, Director, Discovery Chemistry & Technology, AbbVie
- Paul Richardson, Director, Pfizer
- Ilona Kariv, Director, Cellular Pharmacology, Merck
- Adeela Kamal, Senior Director, Therapeutic Area Head for Urology & Translational Research, Ferring Pharmaceuticals
- Matt Wagoner, Associate Director, Mechanistic & Investigative Toxicology, Drug Safety Research & Evaluation, Takeda
- Ping Tsui, Associate Director & Principal Scientist, Antibody Discovery & Protein Engineering, MedImmune
- Sujatha Gopalakrishnan, Head of High Throughput Screening & Molecular Characterization, and Senior Principal Research Scientist, AbbVie
- Govinda Bhissetti, Head of Computational Chemistry and Principal Investigator, Biogen
- Paula Loria, Associate Research Fellow, Pfizer
- Florian Puehler, Alliance Manager, Bayer
- Jeffrey Strovel, CEO and President, Convergene
- Patrick Liu, Founder, President & CEO, Sirnaomics
- Wenqing Yao, Executive Vice President, Discovery Chemistry, Incyte Corporation
- Tom Coulter, Senior Vice President, Midatech Pharma
- Jesse Smith, Vice President of Biological Sciences, Epizyme
- Ron Alfa, Vice President, Discovery & Product, Recursion Pharma
- Steve Potts, Vice President, Global Medical & Diagnostic Affairs, Ignyta
- Thomas Franch, Chief Scientific Officer, Nuevolution
- Torsten Herbertz, Director of Computational Chemistry, Forma Therapeutics
- Matthew Bursavich, Associate Director, Morphic Therapeutics
- Andrew Alt, Associate Director, Biology, Arvinas
- Katherine Kayser-Bricker, Head of Automated Synthesis and Principal Scientist, Technology Enabled Chemistry, Forma Therapeutics
- Leena Otsomaa, Head of Medicinal Chemistry, Orion Corporation
- Christopher Arico-Muendel, Manager, GlaxoSmithKline
- Martin Pettersson, Medicinal Chemistry Group Leader, Pfizer
- Philip Cheung, Bioinformatics / Computer Biology Group Leader, Dart Neuroscience
- Steve Swann, Computational Sciences Group Leader and Principal Scientist, Takeda
- Jonas Bostrom, Principal Scientist, AstraZeneca
- Sepideh Alshar, Principal Scientist, Eli Lilly
- John McCarter, Principal Scientist, Lead Discovery, Amgen
- Michael Jackson, Senior Vice President Drug Discovery & Development, Sanford Burnham Prebys Medical Discovery Institute
- Ruben Abagyan, Professor & Lab Head, University of California Los Angeles
- A. Joshua Wand, Professor, Johnson Research Foundation and Department of Biochemistry & Biophysics, University of Pennsylvania Perelman School of Medicine
- Adam Renslo, Co-Director, Small Molecule Discovery Centre, University of California San Francisco

2017 Drug Discovery and Biomarkers USA Congress Confirmed Sponsors Include:

If you’re on Twitter, make sure to follow us @DrugDiscoveryUS and join the Congress conversation on #DDSUS17

For more information please contact marketing@oxfordglobal.co.uk
# 4th Annual Drug Discovery USA Congress

**Day 1 – 9th October 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30 – 08.20</td>
<td>Registration</td>
</tr>
<tr>
<td>08.20 – 08.25</td>
<td>Oxford Global’s Welcome Address</td>
</tr>
<tr>
<td>08.25 – 08.30</td>
<td>Chairperson’s Opening Address</td>
</tr>
<tr>
<td>08.30 – 09.00</td>
<td>Keynote Address&lt;br&gt;The Importance Of Small Molecule Chemistry In Drug Discovery&lt;br&gt;Spiros Liras, Vice President, Medicinal Chemistry, Pfizer</td>
</tr>
<tr>
<td>09.00 – 09.30</td>
<td>Drug Discovery Innovation And Strategies; Enabling Technologies For Immuno-therapy, Autoimmune Diseases &amp; Oncology&lt;br&gt;Discovery Chemistry: Medicinal And Computational Chemistry</td>
</tr>
<tr>
<td>09.00 – 09.30</td>
<td>Concepts In Target-Indication Prioritization&lt;br&gt;• The statistical evaluation of molecular and phenotypic evidence supporting a target-indication pair&lt;br&gt;• How to connect information in a productive way&lt;br&gt;Mark Hurle, Director, Computational Biology, GlaxoSmithKline</td>
</tr>
<tr>
<td>09.30 – 10.00</td>
<td>Solution Provider Presentation</td>
</tr>
<tr>
<td>10.00 – 11.20</td>
<td>Coffee &amp; Refreshments, One to One Meetings x4, Poster Presentation Sessions</td>
</tr>
<tr>
<td>11.20 – 11.50</td>
<td>Discovery And Development Of A First In Class BET/Dopamine Receptor 2 Antagonist&lt;br&gt;Design And Optimization Of Novel Benzopiperazines As Potent Inhibitors Of BET Bromodomains&lt;br&gt;• A protein structure-guided drug design approach was employed to explore small molecule inhibitors of the BET family of bromodomains that were distinct from the known (+)-JQ1 scaffold class&lt;br&gt;• These efforts led to the identification of a series of substituted benzopiperazines with structural features that enable interactions with many of the potency driving regions of the bromodomain binding site&lt;br&gt;• Lipophilic efficiency was a guiding principle in improving potency alongside drug-like physicochemical properties that are commensurate with oral bioavailability&lt;br&gt;• Lead compounds from the series displayed potent biochemical and cellular activity which translated into excellent in vivo activity in the benchmark cell line MV-4-11&lt;br&gt;Jeffrey Strovel, CEO and President, ConverGene</td>
</tr>
<tr>
<td>11.50 – 12.20</td>
<td>Academic And Pharmaceutical Collaborations For Oncology Case Studies&lt;br&gt;Strategic Use Of Fluorine And Analysis Of The Impact Of Fluorine Substitution On P-Glycoprotein Mediated Efflux, Permeability, Lipophilicity And Metabolic Stability&lt;br&gt;• Strategic use of fluorine is an important tactic in lead optimization. However, replacing a hydrogen atom with a fluorine atom leads to a significant increase in molecular weight that is disproportionate to the corresponding increase in molecular volume. This presentation will describe the impact of fluorine on various ADME parameters&lt;br&gt;• We show that increased molecular weight due to introduction of fluorine does not adversely affect P-gp mediated efflux or passive permeability and that Fluorine-Corrected Molecular Weight (MW_{FC}), where the molecular weight of fluorine has been subtracted, is more relevant parameter in drug design&lt;br&gt;• A pairwise analysis of the impact of fluorine substitution on lipophilicity and metabolic stability will also be discussed&lt;br&gt;Martin Pettersson, Medicinal Chemistry Team Leader, Pfizer</td>
</tr>
</tbody>
</table>
## 4th Annual Drug Discovery USA Congress

**Day 1 – 9th October 2017**

### 12.20 – 12.50

**Lung Specific Delivery Using Caveolae Associated Protein PV-1 Antibody Improves Drug Efficacy**

Ping Tsui, Associate Director & Principal Scientist, Antibody Discovery & Protein Engineering, MedImmune

The Story Of Ph III Compound Darolutamide

Leena Otsomaa, Head of Medicinal Chemistry, Orion Corporation

### 12.50 – 13.50

**Lunch, One to One Meetings x2**

### 13.50 – 14.20

**Microphysical Studies Of Toxicity In Drug Discovery**

Matt Wagoner, Associate Director, Mechanistic & Investigative Toxicology, Drug Safety Research & Evaluation, Takeda

**Nanoscale Encapsulation For Optimized Fragment Based Drug Discovery**

- Weak binding is an unfortunate hallmark of “hits” derived from fragment-based libraries
- This often requires direct demonstration of a physical interaction prior to elaboration and functional testing
- Utilizing the reverse micelle as a confined space, we show that solution NMR spectroscopy can be used to efficiently detect weak specific binding; reduce or eliminate non-specific binding; significantly reduce the amount of ligand and protein required; and, most importantly, enter a region of chemical space that is highly desired but difficult to access using existing screening strategies (i.e. weak hydrophilic binders)

A. Joshua Wand, Professor, Johnson Research Foundation and Department of Biochemistry & Biophysics, University of Pennsylvania Perelman School of Medicine

### 14.20 – 14.50

**Solution Provider Presentation**

For sponsorship opportunities please contact [sponsorship@oxfordglobal.co.uk](mailto:sponsorship@oxfordglobal.co.uk)

### 14.50 – 15.20

**Solution Provider Presentation**

For sponsorship opportunities please contact [sponsorship@oxfordglobal.co.uk](mailto:sponsorship@oxfordglobal.co.uk)

### 15.20 – 15.50

**Title To Be Confirmed**

Jesse Smith, Vice President of Biological Sciences, Epizyme

**Exploiting Disruptive Drug Design Technologies At AstraZeneca**

The following topics will be discussed. Development and exploitation of:

- A new blazingly fast virtual screening capability using GPU-tech
- An Oculus Rift based virtual reality for drug designers
- AI and deep-neural nets in predictive modelling

Jonas Bostrom, Principal Scientist, AstraZeneca

### 15.50 – 16.30

**Afternoon Refreshments, One to One Meetings x2, Poster Presentation Sessions**

### 16.30 – 17.00

**Immunotherapeutic Agents With Tumour-Targeting Molecules**

Tom Coulter, Senior Vice President, Research, Midatech Pharma

**A Computational Chemistry Approach To Drug Design**

Torsten Herbertz, Director of Computational Chemistry, Forma Therapeutics

### 17.00 – 17.30

**A RNAi Therapeutic Approach For Cancer Treatment**

Patrick Liu, Founder, President & CEO, Sirnaomics

**Developing Specialist Informatics Tools For Target Identification And Prioritisation**

Philip Cheung, Bioinformatics / Computer Biology Group Leader, Dart Neuroscience

For more information please contact [marketing@oxfordglobal.co.uk](mailto:marketing@oxfordglobal.co.uk)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.30 – 18.30</td>
<td><strong>Roundtable Discussions: Drug Discovery Directors Club</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Roundtable 1 – Strategies Of Structure-based Design</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: Steve Swann, Computational Sciences Group Leader and Principal Scientist, Takeda</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Roundtable 2 – ADMET Evaluation In Drug Discovery</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: To be Confirmed</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Roundtable 3 – Genomic Approaches To Drug Discovery</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: To be Confirmed</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Roundtable 4 – Latest Trends In Medicinal Chemistry</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: To be Confirmed</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Roundtable 5: CNS Drug Discovery</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: To be Confirmed</strong></td>
</tr>
<tr>
<td>18.30</td>
<td><strong>Networking Drinks, End of Day One</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 08.00 – 08.30 | **Keynote Address:**  
Chemistry And Chemical Biology Technologies For Improving Probability Of Success  
- The dearth of novel targets has increased the pressure to develop novel technologies to enable more rapid and high quality go/no-go decisions  
- This talk will describe some of the recent chemistry, target identification and validation technologies developed at AbbVie  
Anil Vasudevan, Director, Discovery Chemistry & Technology, AbbVie |
| 08.30 – 09.00 | **CNS Discovery In The Mood Space: Lead Optimization For Potential Development Candidates**  
Michael Letavic, Scientific Director & Fellow, Janssen |
| 09.00 – 09.30 | **GSMS For Familial Alzheimer’s Disease**  
Matthew Bursavich, Associate Director, Morphic Therapeutics |
| 09.30 – 10.00 | **Developing Targeted Therapies For CNS Primary And Metastatic Disease**  
Steve Potts, Vice President, Global Medical & Diagnostic Affairs, Ignyta |
| 10.00 – 11.00 | Coffee & Refreshments, One to One Meetings x4, Poster Presentation Sessions |
| 11.00 – 11.30 | **Solution Provider Presentation**  
For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk |
| 11.30 – 12.00 | **Solution Provider Presentation**  
For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk |
| 12.00 – 12.30 | **Therapeutics For CNS Disorders**  
Richard Gatti, Distinguished Professor Emeritus, University of California Los Angeles |
| 12.30 – 13.30 | **Exhibition Room**  
Lunch, One to One Meetings x2  
Part 2: Successful Phenotypic Drug Discovery, High Throughput Technologies And RNAi Screening  
**Discovery Chemistry: Medicinal Chemistry And Novel Approaches To Drug Design** |
| 13.30 – 14.00 | **Massive Parallelization Of Rare Disease Drug Discovery**  
- Recursion combines Artificial Intelligence and automated biology to rapidly screen drugs against hundreds of rare genetic disease in near parallel  
- In just 12 months we have generated a large early discovery pipeline in over 20 rare genetic diseases  
- We have re-discovered therapeutic candidates currently in Phase 2 for several rare genetic diseases as early validation of our approach  
Ron Alfa, Vice President, Discovery & Product, Recursion Pharma  
**Role Of MLKL Activation In Necroptosis And Its Inhibition By NSA – A Molecular Dynamics Study**  
Govinda Bhisetti, Principal Investigator and Head of Computational Chemistry, Biogen |

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.30</td>
<td>Phenotypic Drug Discovery Of The First PCSK9 Secretion Inhibitors</td>
<td>Paula Loria, Associate Research Fellow, Pfizer</td>
<td>DNA Encoded Libraries To Develop A Pipeline Of Cancer Therapeutics</td>
</tr>
<tr>
<td>14.30 – 15.00</td>
<td>Leveraging Phenotypic Screens For Novel Target And Pathway Discovery</td>
<td>Ilona Kariv, Director, Cellular Pharmacology, Merck</td>
<td>Discovery and Synthesis Of The Macrocyclic EML4-ALK Inhibitor lorlatinib</td>
</tr>
<tr>
<td>15.00 – 15.30</td>
<td>Afternoon Refreshments, Poster Presentation Sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td>Affinity MS: Application In Drug Discovery</td>
<td>John McCarter, Principal Scientist, Lead Discovery, Amgen</td>
<td>Multi-target Pharmacology Of Drugs: The Opportunity And The Application</td>
</tr>
<tr>
<td>16.00 – 16.30</td>
<td>High Throughput Screening Of Modulators</td>
<td>Sujatha Gopalakrishnan, Head of High Throughput Screening &amp; Molecular Characterization, and Senior Principal Research Scientist, AbbVie</td>
<td>Targeted Covalent Inhibitors</td>
</tr>
<tr>
<td>16.30 – 17.00</td>
<td>High-throughput Drug Screening For The Development Of Small Molecule Therapeutics</td>
<td>Michael Jackson, Senior Vice President Drug Discovery &amp; Development, Sanford Burnham Prebys Medical Discovery Institute</td>
<td>DNA Encoded Library Technology At GlaxoSmithKline</td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td>Combining High-throughput Screening With Structural And Mechanistic Data To Support The Optimization Of Potential Drug-like Molecules</td>
<td>Reserved: Matthias Frech, Head of Molecular Interaction &amp; Biophysics, Merck</td>
<td>Delegates are welcome to attend co-located presentations</td>
</tr>
<tr>
<td>17.30</td>
<td>End of Congress</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates.

Title: ___________________________ Forename: ___________________________ Surname: ___________________________

Job Title: __________________________________________________________

Company/Organisation: _____________________________________________

Email: ___________________________

Address: __________________________________________________________

Postcode: ___________________________

Country: ___________________________

Direct Telephone: ___________________________ Direct Fax: ___________________________

Mobile: ___________________________ Switchboard: ___________________________

Signature: ___________________________

Date: ___________________________

Registration Fees

I would like to attend: (Please tick as appropriate)

<table>
<thead>
<tr>
<th>Industry Delegates (Biopharma, Pharma or Biotech) Companies</th>
<th>Congress</th>
<th>Day 1</th>
<th>Day 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>£840 / $1,090</td>
<td>£520 / $680</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Academic Delegates</th>
<th>Congress</th>
<th>Day 1</th>
<th>Day 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>£520 / $680</td>
<td>£310 / $420</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vendor Delegates (CROs, Consultants, Technology and Service Providers)</th>
<th>Congress Only</th>
<th>Day 1</th>
<th>Day 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>£1,350 / $1,750</td>
<td>£830 / $1,080</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Poster Presentation | £250 / $345 |

PROMOTIONAL LITERATURE DISTRIBUTION

Distribution of your company’s promotional literature to all conference attendees: £999 / $1,300

Terms & Conditions of Booking

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

Delegate Booking Fee

The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 / $75 will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.

Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

Poster Presentations

Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size.

Cancellation and Curtailment

Delegates and vendor delegates are subject to the following charges and refunds on withdrawal or cancellation.

More than 6 months prior: 35% cancellation fee / 65% refund
Between 6 and 3 months prior: 75% cancellation fee / 25% refund
Less than 3 months prior: no refund

Data Protection

The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Organiser consents to the use of his/her personal and company information on the terms set out herein.

Miscellaneous

This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.

☐ I agree to the above Terms and Conditions

Documentation

I cannot attend but would like to purchase access to the following:

☐ Access to the online conference presentations £499 / $660
☐ Conference presentations - paper copy £499 / $660

Number of delegates:

Ind: ___________ Ac: ___________ V: ___________

Special Offer: 3 for 2

Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD: ☐ Visa ☐ MasterCard ☐ Maestro ☐ Amex

Credit Card Number:

Valid from: 00/00 Expiry Date: 00/00

Security code: 0000

Cardholders name: ___________________________

Signature: ___________________________ Date: ___________________________

☐ PLEASE INVOICE ME: Invoice Address (if different from above)

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk

If you register and pay by 8 November 2017, you will receive a £50 / $75 handling charge for payment via invoice.

*All card payments will be subject to a 3% bank charge or 4% AMEX charge.